We talked with them about our company Trained Therapeutix Discovery. With platform technology from Willem Mulder and immunological insights from Mihai Netea, we develop innovative medicines for the treatment of cancer and inflammatory diseases, among others.

Trained Therapeutix Discovery (“TTxD”) announces that it has extended its Scientific Advisory Board to include James P. Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. Dr. Allison received the 2018 Nobel Prize in Physiology or Medicine for his work on discovering immune checkpoint blockade and is the Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. Dr. Sharma is a pioneer and world-renowned expert in designing and running immuno-oncology clinical trials and is a practicing immunologist and oncologist at MD Anderson Cancer Center.

Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, announces the appointment of Prof. Dr. Willem Mulder as Chief Scientific Officer effective 1 January 2021.

Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, notes the results of a preclinical Study (“the Study”) published in Cell showing how nanobiologic immunotherapy promotes trained immunity and elicits a durable anti-tumor response either as a monotherapy or in combination with other checkpoint inhibitor drugs.

Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, notes the results of a clinical trial¹ (“the Trial”) published in Cell showing that trained immunity through the use of BCG vaccination can reduce respiratory tract infections by 80% amongst elderly people including, potentially, COVID-19.